Paper40511544
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).
Lyu X and 4 others. Int J Oncol, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review). Papers, record 40511544. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40511544
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Neoplasms | Major topic |
| Immunotherapy | Major topic |
| CD8-Positive T-Lymphocytes | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Animals | |
| Lymphocytes, Tumor-Infiltrating |
Source PubMed
References260
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18765557 | CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18765557 | PubMed |
| 2 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 3 | 28928380 | Predictors of responses to immune checkpoint blockade in advanced melanoma. | Nat Commun | 2017 | https://conductscience.org/library/papers/28928380 | PubMed |
| 4 | 29769722 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. | Nature | 2018 | https://conductscience.org/library/papers/29769722 | PubMed |
| 5 | 28423487 | Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. | Oncotarget | 2017 | https://conductscience.org/library/papers/28423487 | PubMed |
| 6 | 37008996 | Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses. | Discov Immunol | 2023 | https://conductscience.org/library/papers/37008996 | PubMed |
| 7 | 35120598 | Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. | Cancer Cell | 2022 | https://conductscience.org/library/papers/35120598 | PubMed |
| 8 | 33178203 | Localized Interleukin-12 for Cancer Immunotherapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33178203 | PubMed |
| 9 | 34031618 | Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. | Nat Immunol | 2021 | https://conductscience.org/library/papers/34031618 | PubMed |
| 10 | 37046094 | Antibodies against endogenous retroviruses promote lung cancer immunotherapy. | Nature | 2023 | https://conductscience.org/library/papers/37046094 | PubMed |
| 11 | 18797453 | Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. | Mol Ther | 2008 | https://conductscience.org/library/papers/18797453 | PubMed |
| 12 | 35593358 | Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. | Curr Drug Targets | 2022 | https://conductscience.org/library/papers/35593358 | PubMed |
| 13 | 30647082 | The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30647082 | PubMed |
| 14 | 28167454 | Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. | Eur J Cancer | 2017 | https://conductscience.org/library/papers/28167454 | PubMed |
| 15 | 35472220 | In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. | J Exp Med | 2022 | https://conductscience.org/library/papers/35472220 | PubMed |
| 16 | 34516744 | Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. | Sci Immunol | 2021 | https://conductscience.org/library/papers/34516744 | PubMed |
| 17 | 31275310 | Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. | Front Immunol | 2019 | https://conductscience.org/library/papers/31275310 | PubMed |
| 18 | 33055204 | Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/33055204 | PubMed |
| 19 | 26989092 | Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. | Int Immunol | 2016 | https://conductscience.org/library/papers/26989092 | PubMed |
| 20 | 27178742 | Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27178742 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42317337 | STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model. | Front Immunol | 2026 | https://conductscience.org/library/papers/42317337 | PubMed |
| 41928274 | Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41928274 | PubMed |
| 41601689 | Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. | Front Immunol | 2025 | https://conductscience.org/library/papers/41601689 | PubMed |
| 41153357 | Spotlight on FAM72B: Pan-Cancer Expression Profiles and Its Potential as a Prognostic and Immunotherapeutic Biomarker. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/41153357 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40511544
GET https://conductscience.org/api/papers/v1/40511544/references?page=2